Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hepatitis B adjuvanted vaccine · 3 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Hepatitis B adjuvanted vaccine | BIOLOGICAL | - |
| Engerix-B | BIOLOGICAL | - |
Inclusion Criteria: * Subjects were to have completed primary vaccination course. A male or female \> = 15 years of age at the time of the first vaccination. * Written informed consent obtained from the subject/ from the parents or guardians of the subject. * If the subject was a female, she was of...
Hepatitis B adjuvanted vaccine is an investigational vaccine being developed for the prevention of Hepatitis B. It is currently in Phase 3 clinical development, with studies conducted in pre- and haemodialysis patients aged 15 years and older. The vaccine is designed to provide protection against Hepatitis B infection.
Hepatitis B adjuvanted vaccine is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting Phase 3 clinical trials to evaluate the vaccine's safety and efficacy in preventing Hepatitis B.
Hepatitis B adjuvanted vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. Three Phase 3 trials have been completed, with a total enrollment of 426 participants.
Hepatitis B adjuvanted vaccine has been studied in three completed Phase 3 trials: NCT00383227, NCT00383383, and NCT00383591. These trials compared the adjuvanted vaccine to a double dose of Engerix-B in pre- and haemodialysis patients aged 15 years and older.
No, Hepatitis B adjuvanted vaccine is not the same as Engerix-B. In clinical trials, the adjuvanted vaccine was compared to a double dose of Engerix-B, which is a standard Hepatitis B vaccine. The adjuvanted vaccine is a separate investigational product being developed by GSK.